Please login to the form below

Not currently logged in
Email:
Password:

Eisai opens first office in Australia

New Melbourne base to support marketing of Halaven and Fycompa
EISAI

Japan-based pharma firm Eisai has extended its global expansion with a new office in Melbourne, Australia.

The office will provide Eisai with a platform to market its portfolio of oncology and epilepsy products, leading with breast cancer treatment Halaven (erbulin) and epilepsy drug Fycompa (perampanel).

Gary Hendler, president and CEO of Eisai EMEA, said: "The launch of the new Eisai office recognises that Australia has an important and distinctive healthcare system."

Halaven received reimbursement in Australia in October and is one of the few breast cancer treatments to be approved by the Australian Pharmaceuticals Benefits Scheme (PBS) in recent years.

The drug is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.

Fycompa is the first in a new class of treatment for partial onset seizures, the most common form of epilepsy. It received reimbursement from the PBS in November in contrast to its fate in Germany where it was turned down for national use by the G-BA last week.

Dr John Bower, market access and medical director of Eisai Australia, said: "While these two products will be our initial focus, Eisai also has an exciting pipeline in oncology, neurology, and the vascular and gastrointestinal fields.”

Eisai has expanded into other markets in recent years, including Russia, where Halaven was launched last year, and in Belgium, where the company created a new office in Brussels.

Article by
Kirstie Pickering

11th November 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics